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Abstract
Background: Genetic association studies of blood pressure (BP) have mostly been 
conducted in non‐African populations. Using the Entebbe Mother and Baby Study 
(EMaBS), we aimed to identify genetic variants associated with BP among Ugandan 
adolescents.
Methods: Systolic and diastolic BP were measured among 10‐ and 11‐year olds. 
Whole‐genome genotype data were generated using Illumina omni 2.5M arrays 
and untyped variants were imputed. Genome‐wide association study (GWAS) was 
conducted using linear mixed model regression to account for population structure. 
Linear regression analysis was used to assess whether variants previously associated 
with BP (p < 5.0 × 10−8) in published BP GWASs were replicated in our study.
Results: Of the 14 million variants analyzed among 815 adolescents, none reached 
genome‐wide significance (p < 5.0×10−8) for association with systolic or diastolic BP. 
The most strongly associated variants were rs181430167 (p = 6.8 × 10−7) for systolic 
BP and rs12991132 (p = 4.0 × 10−7) for diastolic BP. Thirty‐three (17 single nucleo-
tide polymorphisms (SNPs) for systolic BP, 15 SNPs for diastolic BP and one SNP for 
both) of 330 variants previously identified as associated with BP were replicated in this 
study, but none remained significant after accounting for multiple testing.
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1 |  INTRODUCTION
Genome‐wide association studies (GWAS) predominantly 
from Caucasian and Asian populations have identified sev-
eral single nucleotide polymorphisms (SNPs) associated with 
blood pressure (BP; Cho et al., 2009; Evangelou et al., 2018; 
Levy et al., 2009; Qian, Lu, Tan, Liu, & Lu, 2007; Warren et 
al., 2017; Xi et al., 2014). Despite having a high burden of 
hypertension, and opportunities for improved fine‐mapping 
of causative variants, including higher genetic diversity and 
lower linkage disequilibrium (LD; Addo, Smeeth, & Leon, 
2007; Luoni et al., 2005; Noubiap et al., 2017; Tishkoff et 
al., 2009), African populations are underrepresented in pub-
lished genetic studies of BP (Peprah, Xu, Tekola‐Ayele, & 
Royal, 2015). Among 38 studies that investigated genetic 
polymorphisms associated with hypertension in Africa‐based 
populations (participant numbers ranging from 65 to 1939) 
reviewed in (Yako et al., 2018), all adopted a candidate gene 
approach rather than conducting a GWAS. It remains unclear 
whether variants associated with BP in non‐African popula-
tions also influence BP among Africans or whether the pat-
terns of genetic susceptibility differ markedly.
Blood pressure GWASs conducted among populations of 
African origin in the diaspora are rare, and often report dif-
ferent variants associated with BP compared to those reported 
in non‐African populations (Adeyemo et al., 2009; Fox et al., 
2011; Franceschini et al., 2013; Kidambi et al., 2012; Liang et 
al., 2017). Attempts to replicate genetic findings in indepen-
dent populations have returned mixed results (Kayima et al., 
2017; Kidambi et al., 2012; Li et al., 2017; Xi et al., 2014). 
The largest African American GWAS of BP included a meta‐
analysis of 29,378 individuals, and identified only one (the 
SOX6 locus) of the five loci that were associated with BP in 
a multiethnic (African American, European and East Asian) 
sample of 99,382 individuals (Franceschini et al., 2013). Of 
the 17 SNPs most strongly associated with BP (p < 1 × 10−4) 
in African Americans, three SNPS were replicated (p < .05) 
in a West African sample (Adeyemo et al., 2009). Among 
Ugandan adults, 11 out of 27 BP related candidate SNPs 
(selected because of previous association with BP from BP 
GWASs or admixture mapping analysis) were replicated 
(p < .05) with eight of the 11 SNPs having the same effect 
direction as in the discovery sample (Kayima et al., 2017).
Twin studies report that over 30% of BP variability is her-
itable (Biron, Mongeau, & Bertrand, 1976; Williams et al., 
1991) but established variants associated with BP account 
for only 2%–5% of BP variation (Ehret & Caulfield, 2013; 
Salfati, Morrison, Boerwinkle, & Chakravarti, 2015). This 
strongly suggests the existence of important undiscovered 
variants. This “missing heritability” could be due to rare or to 
common SNPs, all conferring small increases or decreases in 
expected BP (Maher, 2008; Manolio et al., 2009). There is a 
need for both GWAS and replication studies to further eluci-
date and improve the generalizability of BP genetic findings.
The role of environmental and of lifestyle factors in hyper-
tension among Africans is well documented as reviewed pre-
viously (Addo et al., 2007; Noubiap et al., 2017). Previously, 
we described the role of environmental and of lifestyle fac-
tors in adolescents’ BP and the findings were reported in 
(Lule, Namara, Akurut, Lubyayi, et al., 2019; Lule, Namara, 
Akurut, Muhangi, et al., 2019). However, the contribution of 
genetic variants remains unknown and understudied (Yako et 
al., 2018). It is not clear whether genetic loci associated with 
hypertension among populations of non‐African origin influ-
ence susceptibility to or protection from hypertension in pop-
ulations on the African continent. Independent confirmation 
is necessary to validate BP SNPs in different populations. We 
used data from the Entebbe Mother and Baby Study (EMaBS) 
birth cohort (Elliott et al., 2007) to conduct 1) a GWAS of 
systolic and diastolic BP and 2) a replication study of can-
didate SNPs identified in previously published BP GWASs. 
The GWAS aimed to identify novel BP loci unique to this 
population while candidate gene analysis aimed to identify 
variants influencing BP across different ethnic groups.
We hypothesized that genetic variants (either unique or 
not unique to populations in Africa) would be associated 
with BP among Ugandan adolescents. Individuals of African 
origin have different genetic makeup from individuals of 
non‐African ancestries (Addo et al., 2007; Luoni et al., 2005; 
Noubiap et al., 2017; Tishkoff et al., 2009). Identifying ge-
netic variants associated with BP enhances our understanding 
of BP regulation and might highlight potential drug targets 
for hypertension treatment and prevention. Furthermore, the 
identification of variants associated with hypertension in 
both adolescence and adulthood could offer opportunities for 
early risk prediction.
European Union. The views expressed are 
those of the authors and not necessarily 
those of the Wellcome Trust, the UK 
Medical Research Council, the Department 
for International Development, the 
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the National Health Service, the National 
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Department of Health.
Conclusion: Variants showing suggestive associations are worthy of future investi-
gation. Replication results suggest that variants influencing adolescent BP may over-
lap somewhat with those already established in previous studies, largely based on 
adults in Western settings.
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2 |  METHODS
2.1 | Ethical compliance
This study was approved by the Uganda Virus Research 
Institute Science and Ethics Committee; the Uganda National 
Council for Science & Technology; the London School of 
Hygiene & Tropical Medicine; and the Oxford Tropical 
Research Ethics Committee. Written informed assent and 
consent were obtained.
2.2 | Study design, population and setting
The EMaBS [trial registration ISRCTN32849447] in Uganda, 
was originally designed to investigate the influence of worms 
and their treatment in pregnancy and early childhood on vac-
cine response and on infections in childhood (Elliott et al., 
2007). Briefly, between April 2003 and November 2005, 
2,507 pregnant women in their second or third trimester were 
randomized in a 2 × 2 factorial design to receive single dose 
albendazole (400 mg) or matching placebo and single dose 
praziquantel (40 mg/kg) or matching placebo. At 15 months 
of age, the resulting 2,345 live‐born infants were randomized 
to receive quarterly albendazole or matching placebo up to 
5 years of age.
2.3 | Phenotyping
The offspring continued under follow‐up after the trial ended 
in 2011. From 20 May 2014 to 16 June 2016, cohort partici-
pants who were now aged 10–11 years were enrolled in a BP 
sub‐study, as part of which additional anthropometric and BP 
data were collected (Lule, Namara, Akurut, Muhangi, et al., 
2019). Adolescents were included in this study if they were 
aged 10 or 11 years and attending their routine annual follow‐
up visit during the BP sub‐study period (11‐year‐olds who 
had previously enrolled as 10‐year‐olds were not included 
twice). Where necessary, enrollment was postponed until the 
participant was free of malaria (fever or axillary temperature 
≥37.5°C and parasitemia) and other illnesses (Lule, Namara, 
Akurut, Muhangi, et al., 2019).
BP was measured as previously described (Lule, Namara, 
Akurut, Muhangi, et al., 2019). Briefly, on the BP study visit 
day, after 5  min rest period, trained nurses measured BP 
thrice 5 min apart, on the right arm supported at the heart 
level, with the participant seated upright all the way to the 
back of the chair, with legs uncrossed and feet flat on the 
floor. Automated Omron (M6, HEM‐700) machines validated 
every 6 months by the Uganda National Bureau of Standards 
were used. Blood pressure phenotypes for this analysis were 
the mean of the second and third readings for systolic and 
diastolic BP, that is, systolic and diastolic BP were analyzed 
as two separate phenotypes. The second and third BP read-
ings were, on average, lower than the first BP reading but 
similar to each other for both systolic and diastolic BP (Lule, 
Namara, Akurut, Muhangi, et al., 2019).
2.4 | Genotyping and quality control
Earlier in 2013, whole‐genome genotyping of 1,391 EMaBS 
participants was undertaken. Genotypic data were generated 
from red cell pellets that had been separated and stored at 
−80°C until processing. Approximately 2.2 million genetic 
variants were generated at Wellcome Sanger Institute using 
the Illumina HumanOmni2.5M‐8 (“octo”) Beadchip arrays, 
version 1.1 (Illumina Inc.). Quality control (using standard 
pipelines) was performed at the University of Oxford using 
commands in PLINK (version 1.7; Purcell et al., 2007) to 
remove individuals and variants with high levels of missing-
ness or deviations from expected levels of heterozygosity or 
Hardy–Weinberg equilibrium (p < 1 × 10−8). Untyped ge-
netic variants and the variants identified for replication analy-
sis were imputed in the EMaBS sample using a merged panel 
(1,000 Genomes Project Consortium et al., 2015, African 
genome variation project [AGVP] Gurdasani et al., 2015 
and Uganda 2000 Genomes [UG2G]: genomes of Ugandan 
individuals of diverse ethnicity from rural Uganda) at the 
Wellcome Centre for Human Genetics. SHAPEIT2 (ver-
sion 2 790; O'Connell et al., 2014), and IMPUTE2 (version 
2.3.2; Marchini, Howie, Myers, McVean, & Donnelly, 2007) 
were used for imputation using settings as recommended for 
African populations. Only SNPs with an INFO score >0.3 
and a minor allele frequency >0.01 were taken forward for 
analysis.
2.5 | Association analysis
The analysis included EMaBS adolescents with phenotypic 
and genotypic data. The two outcomes (mean systolic BP and 
mean diastolic BP) were analyzed separately. GWAS of BP 
(systolic and diastolic) as quantitative traits was done using 
mixed linear regression methods (accounting for population 
substructure) assuming an additive model and controlling for 
age and body mass index (BMI) as covariates in genome‐
wide complex trait analysis (GCTA) version 1.22 (Yang, 
Lee, Goddard, & Visscher, 2011). A p < 5 × 10−8 was con-
sidered as the threshold to denote genome‐wide significance 
for SNPs. Results for SNPs with p < 1 × 10−6 are reported. 
Manhattan plots and Quantile–Quantile (Q–Q) plots were 
constructed to show the distributions of association p‐val-
ues and the departure of the observed p‐values from the null, 
respectively.
For the replication component of this study, previously 
published BP GWASs were searched to identify SNPs reported 
to be associated with systolic or diastolic BP (p < 5 × 10−8 
in the original GWAS) and these variants were considered 
for the replication. Replication analysis was conducted using 
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linear regression adjusting for age and BMI in Stata version 
14 (College Station, Texas, USA). Variants were tested for 
association with the phenotype they were associated with in 
the published GWAS, that is variants associated with systolic 
BP in a published GWAS were tested for association with 
systolic BP but not with diastolic BP and vice versa. P < .05 
was considered the threshold for statistical significance for 
the replication study although results were also interpreted in 
light of a Bonferroni correction allowing for all tests done in 
the replication analysis.
The base pair position is based on the Genome Reference 
Consortium Human Build 37, February 2009 (GRCh37/
hg19).
3 |  RESULTS
The discovery GWAS analysis used data on 20,074,711 SNPs 
from 815 adolescents. These adolescents had a mean age of 
10.4 years, a mean BMI of 16.0 kg/m2, mean systolic BP of 
106.0 mmHg, and mean diastolic BP of 65.3 mmHg. Four 
hundred and seventeen (51%) of the adolescents were male. 
Detailed characteristics of EMaBS participants included 
and not included in the analysis are described in Table S1. 
Offspring included in the genetic analysis were similar for 
most characteristics to those not included, except that those 
included were more likely to have been delivered in Entebbe 
hospital than elsewhere and to have been exclusively breast-
feeding at 6 weeks of age.
The distributions of association p‐values (Manhattan plot) 
for systolic and diastolic BP phenotypes are shown in Figure 
1 and the Q–Q plots in Figure 2. The observed P‐values show 
no departure from the null (Figure 2), either for systolic or 
diastolic BP, with lambda values of 1.006 and 0.995, respec-
tively. The results show adequate control for population sub-
structure in the analysis.
The SNPs most strongly associated with BP are shown 
in Table 1. None of the SNPs reached genome‐wide level 
of significance (p  <  5  ×  10−8) for association with ado-
lescent systolic or diastolic BP. Borderline significance 
(5 × 10−8 < p < 1 × 10−6) for association with systolic BP 
was achieved for four index SNPs at four separate loci; there 
were four SNPs showing borderline significant associations 
with diastolic BP at four separate loci. There was no overlap 
between the SNPs most strongly associated with systolic BP 
and those most strongly associated with diastolic BP. None 
of these index SNPs have been identified as associated with 
BP in previously published BP GWAS. The most strongly 
associated SNP for systolic BP with p‐value 6.8 × 10−7 was 
rs181430167, located in the intron region of KLHL29 on 
chromosome 2. The lowest p‐value (4.0 × 10−7) for associ-
ation with diastolic BP was for rs12991132 located between 
ZFP36L2, THADA, LOC1001297261 on chromosome 2.
Of the 389 SNPs (Adeyemo et al., 2009; Cho et al., 2009; 
Ehret et al., 2016; International Consortium for Blood Pressure 
Genome‐Wide Association Studies et al., 2011; Evangelou et 
al., 2018; Fox et al., 2011; Franceschini et al., 2013; Ganesh 
et al., 2014, 2013; Ho et al., 2011; Hoffmann et al., 2017; 
Johnson, Newton‐Cheh, et al., 2011; Johnson, Gaunt, et al., 
2011; Kato et al., 2015, 2011; Kidambi et al., 2012; Levy 
et al., 2009; Li et al., 2017; Liang et al., 2017; Liu et al., 
2016; Newton‐Cheh, Johnson, et al., 2009; Newton‐Cheh, 
Larson, et al., 2009; Parmar et al., 2016; Simino et al., 2014; 
Surendran et al., 2016; Takeuchi et al., 2010; Tragante et al., 
2014; Wain et al., 2017, 2011; Warren et al., 2017) identified 
for replication, 330 (85%) SNPs were included in the replica-
tion analysis. Fifty‐nine SNPs that were either rare (<0.01) 
or poorly imputed (INFO score <0.3) in the EMaBS sample 
were not included in the replication analysis. Thirty SNPs of 
the 330 SNPs included in the replication had been previously 
associated with BP in populations of African origins. Forty 
SNPs had been previously associated with both systolic and 
F I G U R E  1  Manhattan plots for the association of SNPs with (a) systolic blood pressure and (b) diastolic blood pressure adjusting for age and 
body mass index as fixed covariates
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diastolic BP and were tested for association with both. Tables 
2 and 3 show results from the replication analysis. Briefly, 33 
SNPs (17 for systolic, 15 for diastolic and one for both systolic 
and diastolic BP) were associated with BP in this population, 
with the same effect direction as the discovery population for 
14 of the SNPs (five for systolic BP and eight for diastolic BP 
and one for both systolic and diastolic BP).
Of the 30 SNPs previously known to be associated 
with BP specifically in individuals of African origin, three 
(ATP2B rs2681492, MDM4 rs2169137 and EVX1/HOXA 
rs17428471) were associated with BP in the present study. 
Only the EVX1/HOXA rs17428471 had the same effect direc-
tion as in the discovery population. The BAT2/BAT5 rs805303 
variant was associated with systolic BP and diastolic BP of 
the 40 SNPs tested for association with both traits. The G al-
lele of the BAT2/BAT5 rs805303 variant was associated with 
higher systolic and higher diastolic BP among adolescents in 
this study: the same effect direction observed in the discovery 
population for both traits.
There were 370 independent tests (197 for systolic BP, 
173 for diastolic BP) conducted, thus approximately 19 SNPs 
(370  ×  0.05  =  18.5) would be expected to be associated 
F I G U R E  2  Quantile–Quantile (Q–Q) plots for the two phenotypes and the genomic control coefficient (lambda). (a) systolic blood pressure 
and (b) diastolic blood pressure
T A B L E  1  Genome‐wide association study results: SNPs associated with blood pressure (systolic or diastolic) at p < 1.0 × 10−7
Chr Nearest genea Positionb SNP
Distance to 
gene (kb) Type EA RA EAF β SE p‐value
Systolic blood pressure
2 KLHL29 23904233 rs181430167 0 Intron C T 0.05 4.62 9.24 6.8 × 10−7
10 LINC00701 2565732 rs71502208 500 Unknown A G 0.22 2.51 5.05 9.3 × 10−7
3 SGOL1/SGOL‐ASI 20295100 rs139992073 200 Unknown C T 0.14 2.83 5.74 9.7 × 10−7




43291689 rs12991132 500 Unknown A G 0.59 −1.87 3.61 4.0 × 10−7
2 COBLL 165534347 rs111770209 20 Unknown T C 0.94 −3.82 7.53 4.8 × 10−7
2 DNAH7 196853830 rs13403027 0 Intron A G 0.71 −1.91 3.87 9.1 × 10−7
4 ANK2 114209732 rs29356 0 Intron T C 0.69 1.91 3.87 9.6 × 10−7
Abbreviations: Chr, chromosomes; EA, effect allele; EAF, effect allele frequency; RA, reference allele; SE, standard error; SNP, single nucleotide polymorphism; β, 
effect size estimates correspond to mean difference in mmHg per effect allele for systolic or diastolic blood pressure, adjusted for age and body mass index.
aNamed according to the nearest annotated gene(s). 
bGiven with respect to Build 37 (GRCh37/hg19). 
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T A B L E  2  Loci associated with systolic blood pressure identified from previous GWAS and results of replication in Entebbe Mother and 
Baby Study (EMaBS) sample
Chr SNP Positiona Nearest gene Population
EA/
RA
Discovery sample EMaBS sample
EAF β SE p‐value EAF βb SE p‐value
1 rs839755 43856410 SZT2 E A/C 0.62 −0.27 0.03 5.4 × 10‒18 0.81 0.29 0.70 6.8 × 10‒1
1 rs4926499 249155909 AL672294.1 E C/G 0.82 0.30 0.04 1.3 × 10‒11 0.98 −5.12 2.00 1.1 × 10‒2
1 rs1043069 180859368 XPR1 E T/G 0.62 0.23 0.03 5.2 × 10‒14 0.63 0.02 0.62 9.7 × 10‒1
1 rs4651224 184585182 C1orf21 E T/C 0.45 0.20 0.03 9.0 × 10‒11 0.94 0.75 1.24 5.5 × 10‒1
1 rs2807337 22577371 WNT4 E T/C 0.37 0.19 0.03 2.8 × 10‒9 0.43 −0.70 0.58 2.3 × 10‒1
1 rs7514579 94051350 BCAR3 E A/C 0.77 0.22 0.03 5.5 × 10‒10 0.50 1.25c 0.67 4.0 × 10‒2
1 rs17396055 94730954 ARHGAP29 E A/G 0.33 −0.17 0.03 4.0 × 10‒8 0.08 0.80 1.02 4.3 × 10‒1
1 rs12042924 197297417 CRB1 E T/C 0.53 −0.18 0.03 2.6 × 10‒9 0.86 −1.29 0.86 1.3 × 10‒1
1 rs7555285 209970355 IRF6 E C/G 0.80 0.23 0.04 1.1 × 10‒9 0.83 −0.52 0.77 5.0 × 10‒1
1 rs33996239 203109801 ADORA1 E T/C 0.06 −0.37 0.07 3.4 × 10‒8 0.09 −0.13 1.08 9.0 × 10‒1
1 rs2932538 113216543 MOV10 E G/A 0.75 0.39 — 1.2 × 10‒9 0.85 0.15 0.80 8.6 × 10‒1
1 rs7515635 42408070 HIVEP3 E T/C 0.47 0.31 0.04 4.8 × 10‒12 0.68 0.08 0.65 9.0 × 10‒1
1 rs17367504 11862778 MTHFR‐NPPB E G/A 0.14 −0.85 0.11 2.0 × 10‒13 0.09 0.66 1.10 5.5 × 10‒1
1 rs2493292 3328659 PRDM16 E/AA T/C 0.15 0.37 0.07 1.4 × 10‒8 0.17 −0.36 0.82 6.6 × 10‒1
1 rs880315 10796866 CASZ1 AS C/T 0.34 1.08 0.03 2.2 × 10‒8 0.11 −0.91 0.96 3.5 × 10‒1
1 rs3820068 15798197 CELA2A E A/G 0.81 0.43 0.06 1.1 × 10‒8 0.63 0.81 0.63 2.0 × 10‒1
1 rs10922502 89360158 GTF2B E A/G 0.62 −0.38 0.05 2.2 × 10‒15 0.67 −0.32 0.64 6.1 × 10‒1
2 rs2972146 227100698 2q36.3 E T/G 0.65 0.17 — 8.4 × 10‒9 0.86 −0.19 0.86 4.0 × 10‒2
2 rs1446468 164963486 FIGN‐GRB14 E T/C 0.53 −0.50 0.07 1.8 × 10‒12 0.95 0.46 1.34 7.3 × 10‒1
2 rs16849225 164906820 FIGN‐GRB14 AS C/T 0.61 0.75 0.11 3.5 × 10‒11 0.89 −1.04 0.93 2.7 × 10‒1
2 rs7562 28635740 FOSL2 E T/C 0.52 0.26 0.05 1.9 × 10‒8 0.26 0.20 0.67 7.6 × 10‒1
2 rs13420463 37517566 PRKD3 E A/G 0.77 0.36 0.05 7.0 × 10‒11 0.45 0.03 0.63 9.6 × 10‒1
2 rs55780018 208526140 METTL21A‐
AC079767.3
E T/C 0.54 −0.39 0.05 5.9 × 10‒16 0.75 0.59 0.74 4.2 × 10‒1
2 rs1275988 26914364 KCNK3 E T/C 0.23 −0.60 0.09 2.6 × 10‒10 0.14 2.01 0.85 1.8 × 10‒2
2 rs6712094 165043460 FIGN‐GRB14 E A/G 0.70 0.60 0.10 9.9 × 10‒9 0.89 −3.72 1.01 2.6 × 10‒4
2 rs1344653 19730845 OSR1 E/AS A/G 0.54 −0.27 0.04 7.8 × 10‒12 0.67 0.07 0.66 9.1 × 10‒1
2 rs2300481 66782467 MEIS1 E T/C 0.39 0.20 0.03 1.6 × 10‒10 0.37 0.73 0.61 2.3 × 10‒1
2 rs35590893 43716933 HADA E A/G 0.27 −0.24 0.03 1.7 × 10‒12 0.13 0.52 0.86 5.5 × 10‒1
2 rs67720684 18975439 NT5C1B E A/C 0.24 0.19 0.04 3.8 × 10‒8 0.36 −0.41 0.60 5.0 × 10‒1
2 rs28377357 112769721 MERTK E A/G 0.29 −0.21 0.03 9.6 × 10‒11 0.31 0.87 0.64 1.8 × 10‒1
2 rs72816333 60096560 RP11−444A22.1 E A/T 0.83 0.23 0.04 5.5 × 10‒9 0.96 −0.15 1.48 9.2 × 10‒1
2 rs28558491 187816321 ZSWIM2 E T/C 0.74 −0.21 0.03 7.5 × 10‒10 0.29 0.55 0.67 4.1 × 10‒1
2 rs6723509 122000745 TFCP2L1 E T/C 0.86 0.25 0.04 7.6 × 10‒9 0.91 0.78 1.00 4.4 × 10‒1
2 rs1044822 230629138 TRIP12 E T/C 0.15 −0.25 0.04 5.2 × 10‒9 0.09 −0.41 1.07 7.0 × 10‒1
2 rs12694277 213188795 ERBB4 E T/C 0.30 −0.20 0.03 1.8 × 10‒9 0.62 −0.05 0.61 9.4 × 10‒1
2 rs6739913 185033065 ZNF804A E A/G 0.28 0.18 0.03 6.5 × 10‒8 0.21 0.21 0.71 7.6 × 10‒1
2 rs2920899 55279681 RTN4 E T/G 0.79 0.20 0.04 9.5 × 10‒8 0.86 1.58c 0.78 4.0 × 10‒2
3 rs9810888 53635595 CACNA1D AS G/T 0.39 0.53 0.10 5.5 × 10‒8 0.60 −1.15 0.60 5.4 × 10‒2
3 rs11128722 14958126 FGD5 E A/G 0.56 −0.31 0.05 3.6 × 10‒11 0.32 0.39 0.10 5.2 × 10‒1
3 rs9859176 134000025 RYK E T/C 0.40 0.32 0.05 1.3 × 10‒11 0.17 0.57 0.77 4.6 × 10‒1
3 rs419076 169100886 MECOM E T/C 0.47 0.41 — 1.8 × 10‒13 0.57 −0.60 0.61 3.2 × 10‒1
3 rs347591 11290122 HRH1 E/AS/AA G/T 0.35 −0.53 0.11 1.5 × 10‒8 0.57 −0.41 0.60 4.9 × 10‒1
3 rs13082711 27537909 SL4A7 E T/C 0.78 −0.24 — 3.8 × 10‒9 0.95 −0.33 1.41 8.1 × 10‒1
(Continues)
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3 rs319690 47927484 MAP4 E T/C 0.50 0.42 0.07 4.7 × 10‒8 0.44 0.72 0.62 2.5 × 10‒1
3 rs12638085 30405936 TGFBR2 E A/T 0.35 0.22 0.03 5.6 × 10‒12 0.12 −1.31 0.92 1.6 × 10‒1
3 rs6788984 41107173 CTNNB1 E A/G 0.86 0.30 0.04 3.8 × 10‒12 0.71 −0.05 0.66 9.4 × 10‒1
3 rs9875380 132780356 TMEM108 E T/C 0.46 −0.18 0.03 6.5 × 10‒9 0.26 −1.55c 0.68 2.3 × 10‒2
3 rs863930 135949737 PCCB E A/C 0.54 0.19 0.03 5.1 × 10‒10 0.63 −0.77 0.62 2.2 × 10‒1
3 rs78151625 158316726 MLF1 E T/C 0.83 −0.25 0.04 1.6 × 10‒9 −0.82 3.49 3.49 8.1 × 10‒1
3 rs6774721 49381898 ARIH2 E C/T 0.88 0.28 0.05 6.4 × 10‒9 0.83 −0.94 0.85 3.7 × 10‒1
3 rs9857362 74710462 CNTN3 E A/C 0.53 0.17 0.03 1.6 × 10‒8 0.83 0.65 0.77 3.9 × 10‒1
4 rs1458038 81164723 FGF5 E T/C 0.29 0.71 — 1.5 × 10‒23 0.04 1.28 1.53 4.1 × 10‒1
4 rs2291435 38387395 TBC1D1‐FLJ13197 E/AA T/C 0.52 −0.34 0.04 1.9 × 10‒14 0.30 −0.54 0.64 4.0 × 10‒1
4 rs13112725 106911742 NPNT E C/G 0.76 0.44 0.06 1.5 × 10‒14 0.61 −0.62 0.60 3.0 × 10‒1
4 rs231708 2694773 FAM193A E C/G 0.69 −0.12 0.03 4.7 × 10‒18 0.24 1.14 0.68 9.6 × 10‒2
4 rs7439567 138464842 P11−714L20.1 E T/C 0.42 0.25 0.03 2.3 × 10‒16 0.81 −0.58 0.76 4.4 × 10‒1
4 rs2610990 18008232 LCORL E A/G 0.26 −0.29 0.03 2.8 × 10‒17 0.19 −1.19 0.77 1.2 × 10‒1
4 rs17035181 157678511 PDGFC E T/G 0.85 0.31 0.04 7.6 × 10‒13 0.75 −1.47 0.71 3.8 × 10‒2
4 rs1347345 95938386 MPR1B E A/G 0.62 −0.18 0.03 6.9 × 10‒9 0.87 0.23 0.88 8.0 × 10‒1
4 rs12511987 46595623 GABRA2 E T/G 0.82 −0.23 0.04 5.4 × 10‒9 0.94 −0.53 1.45 7.2 × 10‒1
4 rs2014912 86715670 ARHGAP24 E/AS T/C 0.16 0.62 0.08 5.4 × 10‒17 0.16 1.16 0.82 1.6 × 10‒1
5 rs13359291 122476457 PRDM6 E/AS A/G 0.31 0.53 0.07 8.9 × 10‒16 0.16 0.66 0.77 3.9 × 10‒1
5 rs1173771 32815028 NPR3‐C5orf23 E G/A 0.60 0.50 — 1.8 × 10‒16 0.82 1.09 0.82 1.9 × 10‒1
5 rs11953630 157845402 EBF1 E T/C 0.37 −0.41 — 3.0 × 10‒11 0.13 −0.34 0.88 7.0 × 10‒1
5 rs10077885 114390121 TRIM36 E A/C 0.50 −0.28 0.04 1.6 × 10‒10 0.65 0.20 0.63 7.5 × 10‒1
5 rs6595838 127868199 FBN2 E A/G 0.30 0.34 0.05 7.6 × 10‒12 0.63 0.62 0.59 2.9 × 10‒1
5 rs1173766 32804528 NPR3 AS C/T 0.60 0.63 0.11 1.9 × 10‒8 0.66 1.13 0.64 7.8 × 10‒1
5 rs10069690 1279790 TERT E T/C 0.26 0.31 0.04 4.8 × 10‒17 0.66 −0.54 0.65 4.0 × 10‒1
5 rs709668 96174186 CTD−2260A17.2 E A/G 0.20 −0.29 0.04 6.0 × 10‒15 0.40 −0.43 0.59 4.7 × 10‒1
5 rs246973 68007803 SLC30A5 E T/C 0.29 0.25 0.03 1.5 × 10‒13 0.40 2.51 1.53 1.0 × 10‒1
5 rs702395 140086677 ZMAT2 E T/C 0.44 0.23 0.03 3.5 × 10‒14 0.29 −0.15 0.65 8.2 × 10‒1
5 rs13179413 55868097 AC022431.2 E T/C 0.28 0.22 0.03 1.1 × 10‒10 0.21 −0.23 0.72 7.5 × 10‒1
5 rs62373688 127352807 CTC−228N24.3 E A/T 0.13 0.27 0.04 1.5 × 10‒9 0.24 1.40c 0.70 4.6 × 10‒2
5 rs74774746 33411769 TARS E C/G 0.26 −0.19 0.04 5.6 × 10‒8 0.14 1.49 0.88 9.2 × 10‒2
5 rs1008058 122435627 PRDM6 E A/G 0.14 0.55 — 3.0 × 10‒10 0.13 0.31 0.89 7.3 × 10‒1
6 rs79030490 134087689 TARID‐TCF21 AA A/C 0.09 −1.83 0.31 3.0 × 10‒9 0.11 0.99 1.19 4.0 × 10‒1
6 rs76987554 134080855 TARID‐TCF21 AA C/T 0.91 1.85 0.31 2.2 × 10‒9 0.90 −0.88 1.20 4.6 × 10‒1
6 rs1799945 26091179 HFE E G/C 0.14 0.63 — 7.7 × 10‒12 0.02 −1.84 2.17 4.0 × 10‒1
6 rs805303 31616366 BAT2‐BAT5 E G/A 0.61 0.38 — 1.5 × 10‒11 0.40 1.66c 0.61 7.0 × 10‒3
6 rs6911827 22130601 CASC15 E T/C 0.45 0.30 0.05 2.0 × 10‒10 0.82 0.81 0.81 3.2 × 10‒1
6 rs2270860 43270151 SLC22A7 E/AA T/C 0.37 0.32 0.05 2.9 × 10‒11 0.78 −1.20 0.71 9.1 × 10‒2
6 rs1563788 43308363 TTBK1‐
SLC22A7‐
ZNF318
E/AS T/C 0.31 0.51 0.06 2.2 × 10‒16 0.78 −1.46 0.71 4.0 × 10‒2
6 rs13209747 127115454 RSPO3 E/AA/AS T/C 0.19 0.85 0.21 2.6 × 10‒10 0.07 −0.13 1.09 9.1 × 10‒1
6 rs17080102 151004770 PLEKHG1 E/AA/AS C/G 0.10 −1.02 0.25 4.8 × 10‒8 0.15 −0.61 0.81 4.5 × 10‒1
6 rs9368222 20686996 CDKAL1 E A/C 0.27 0.23 0.03 1.8 × 10‒11 0.17 −0.07 0.81 9.3 × 10‒1
6 rs10782230 126228512 NCOA7 E A/G 0.48 0.21 0.03 2.9 × 10‒12 0.41 0.71 0.62 2.6 × 10‒1
6 rs2745599 1613686 FOXC1 E A/G 0.55 0.22 0.03 9.8 × 10‒12 0.10 −1.48 0.95 1.2 × 10‒1
T A B L E  2  (Continued)
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6 rs9885632 131311909 EPB41L2 E T/C 0.73 0.24 0.03 4.3 × 10‒12 0.94 0.64 1.39 6.4 × 10‒1
6 rs7763294 140383733 CITED2 E T/G 0.32 −0.20 0.03 6.4 × 10‒10 0.10 0.32 0.97 7.4 × 10‒1
7 rs2969070 2512545 CHST12‐LFNG E A/G 0.63 −0.30 0.05 1.4 × 10‒10 0.97 −0.01 1.80 1.0 × 10‒0
7 rs11556924 129663496 ZC3HC1 E T/C 0.38 −0.28 0.05 7.6 × 10‒9 0.01 −0.24 1.58 8.8 × 10‒1
7 rs13238550 131059056 MKLN1 E A/G 0.40 0.33 0.05 1.9 × 10‒12 0.09 −0.14 1.14 9.0 × 10‒1
7 rs1011018 139463264 HIPK2 E A/G 0.20 −0.33 0.06 1.5 × 10‒8 0.61 −0.17 0.59 7.8 × 10‒1
7 rs4728142 128573967 7q32.1 E A/G 0.43 −0.24 ‐ 3.5 × 10‒8 0.23 −0.27 0.69 7.0 × 10‒1
7 rs17477177 106411858 PIK3CG E T/C 0.72 −0.55 0.08 5.7 × 10‒11 0.94 −0.86 1.15 4.5 × 10‒1
7 rs17428471 27337867 EVX1‐HOXA E/AA/AS T/G 0.14 1.20 0.24 2.1 × 10‒12 0.13 1.39 0.90 1.3 × 10‒1
7 rs11563582 27351650 EVX1‐HOXA AA A/G 0.13 1.61 0.28 7.1 × 10‒9 0.17 0.56 0.81 4.9 × 10‒1
7 rs848445 77572461 PHTF2 E T/C 0.23 −0.20 0.03 2.3 × 10‒9 0.08 −0.09 1.03 9.3 × 10‒1
7 rs6963105 75097488 POM121C E A/G 0.43 −0.19 0.03 3.8 × 10‒9 0.06 0.17 1.15 8.8 × 10‒1
7 rs10274928 28142088 JAZF1 E A/G 0.49 0.16 0.03 8.2 × 10‒8 0.66 −0.05 0.63 9.3 × 10‒1
7 rs11771693 150050111 RARRES2 E A/G 0.67 0.18 0.03 1.9 × 10‒8 0.52 −0.25 0.62 6.8 × 10‒1
8 rs4841569 11452177 BLK‐GATA4 E/AS G/A 0.51 0.47 0.02 5.6 × 10‒10 0.91 0.33 1.13 7.7 × 10‒1
8 rs2898290 11433909 BLK‐GATA4 E T/C 0.53 0.53 0.80 3.2 × 10‒8 0.61 −0.71 0.60 2.3 × 10‒1
8 rs1986971 10268736 MSRA E A/G 0.70 0.26 0.03 1.6 × 10‒14 0.80 1.45c 0.73 4.8 × 10‒2
8 rs1906672 38130025 WHSC1L1 E A/G 0.23 0.30 0.04 1.2 × 10‒16 0.16 0.08 0.82 9.2 × 10‒1
8 rs72688070 81393697 Y_RNA E T/C 0.17 −0.27 0.04 2.8 × 10‒11 0.44 −0.62 0.60 3.0 × 10‒1
8 rs62491354 9730663 TNKS E A/G 0.13 0.31 0.04 3.3 × 10‒12 0.13 −2.38 0.80 3.0 × 10‒3
8 rs4129585 143312933 TSNARE1 E A/C 0.44 0.19 0.03 1.0 × 10‒9 0.06 −1.10 1.18 3.5 × 10‒1
8 rs6557876 25900675 EBF2 E C/T 0.25 −0.37 0.05 2.8 × 10‒14 0.50 −0.20 0.60 7.4 × 10‒1
8 rs894344 135612745 ZFAT E A/G 0.60 −0.26 0.05 3.2 × 10‒8 0.65 −0.17 0.64 8.0 × 10‒1
9 rs10760117 123586737 PSMD5 E T/G 0.42 0.28 0.05 6.1 × 10‒10 0.78 −1.39 0.72 5.3 × 10‒2
9 rs1332813 9350706 PTPRD E T/C 0.35 0.22 0.03 2.3 × 10‒12 0.36 0.02 0.62 9.7 × 10‒1
9 rs7045409 95201540 CENPP E A/T 0.37 −0.19 0.03 2.6 × 10‒9 0.90 2.16 0.94 2.2 × 10‒2
9 rs1891730 130309028 FAM129B E T/C 0.62 −0.18 0.03 7.7 × 10‒9 0.39 −1.13 0.61 6.2 × 10‒2
9 rs28558845 4334791 GLIS3 E C/G 0.16 −0.26 0.04 1.2 × 10‒9 0.24 0.29 0.72 6.9 × 10‒1
10 rs1133400 134459388 INPP5A E A/G 0.79 −0.30 0.04 2.5 × 10‒15 0.86 0.11 0.88 9.0 × 10‒1
10 rs11191548 104846178 CYP17A1‐NT5C2 E T/C 0.91 1.16 0.12 7.0 × 10‒24 0.98 −0.41 1.62 8.0 × 10‒1
10 rs112184198 102604514 PAX2 E A/G 0.10 −0.66 0.08 3.6 × 10‒18 0.06 3.67 1.37 8.0 × 10‒3
10 rs1813353 18707448 CACNB2 E T/C 0.68 0.57 — 2.6 × 10‒12 0.84 −0.74 0.84 3.8 × 10‒1
10 rs932764 95895940 PLCE1 E G/A 0.44 0.48 — 7.1 × 10‒16 0.15 0.59 0.85 4.9 × 10‒1
10 rs1801253 115805056 ADRB1 E G/C 0.27 −0.57 0.09 4.7 × 10‒10 0.34 0.21 0.64 7.5 × 10‒1
10 rs4387287 105677897 OBFC1 E/AS A/C 0.16 0.36 — 9.1 × 10‒10 0.73 −0.00 0.67 1.0 × 10‒0
10 rs4590817 63467553 C10orf107 E G/C 0.84 0.65 — 4.0 × 10‒12 0.84 −0.55 0.78 4.8 × 10‒1
10 rs7912283 133773019 PPP2R2D E A/G 0.35 0.21 0.03 6.4 × 10‒11 0.89 −0.31 0.89 7.3 × 10‒1
10 rs12572586 74751579 PLA2G12B E T/C 0.94 −0.39 0.06 1.2 × 10‒9 0.95 1.91 1.41 1.8 × 10‒1
10 rs11197813 118523933 HSPA12A E A/G 0.70 −0.18 0.03 3.5 × 10‒8 0.82 0.97 0.74 1.9 × 10‒1
10 rs4373814 18419972 CACNB2 E G/C 0.55 −0.37 4.8 × 10‒11 0.39 −0.82 0.60 1.7 × 10‒1
11 rs7103648 47461783 RAPSN‐PSMC3‐
SLC39A13
E A/G 0.61 −0.33 0.05 4.4 × 10‒13 0.85 0.97 0.85 2.6 × 10‒1
11 rs751984 61278246 LRRC10B E T/C 0.88 0.41 0.07 3.8 × 10‒9 0.79 0.04 0.72 9.5 × 10‒1
11 rs661348 1905292 LSP1‐TNNT3 E T/C 0.57 −0.65 0.11 7.0 × 10‒10 0.86 0.89 0.98 3.3 × 10‒1
11 rs7129220 10350538 ADM E G/A 0.89 −0.62 — 3.0 × 10‒12 0.92 −1.02 1.16 3.8 × 10‒1
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11 rs633185 100593538 FLJ32810‐
TMEM133
E G/C 0.28 −0.57 — 1.2 × 10‒17 0.23 −0.92 0.71 2.0 × 10‒1
11 rs4757391 16302939 SOX6 E/AS/AA T/C 0.21 0.56 0.12 5.7 × 10‒10 0.74 0.19 0.65 7.7 × 10‒1
11 rs11229457 58207203 OR5B12 E/AS T/C 0.24 −0.31 — 2.7 × 10‒8 0.29 −0.36 0.62 5.6 × 10‒1
11 rs381815 16902268 PLEKHA7 E T/C 0.26 0.57 — 5.3 × 10‒11 0.26 −0.27 0.71 5.6 × 10‒1
11 rs3741378 65408937 RELA E T/C 0.14 −0.55 — 3.4 × 10‒10 0.76 −1.04 0.69 1.3 × 10‒1
11 rs4385883 51539339 TRIM48 E T/A 0.29 −0.25 0.04 1.4 × 10‒12 0.53 −0.10 0.60 8.6 × 10‒1
11 rs11041530 7701503 CYB5R2 AA C/G 0.11 −1.35 0.25 4.0 × 10‒8 0.17 0.49 0.82 5.5 × 10‒1
11 rs1401454 16250183 SOX6 AA T/C 0.46 0.55 0.16 5.6 × 10‒8 0.46 −0.60 0.59 3.1 × 10‒1
11 rs7941684 5532222 UBQLN3 AA T/G 0.80 −1.23 0.22 2.4 × 10‒8 0.82 −0.69 0.80 3.8 × 10‒1
11 rs11031051 30355707 ARL14EP E A/C 0.69 −0.22 0.03 7.7 × 10‒12 0.58 0.26 0.61 6.7 × 10‒1
11 rs67976715 68023742 C11orf24 E C/G 0.23 0.21 0.04 6.8 × 10‒9 0.07 −2.44 1.23 4.8 × 10‒2
11 rs10743086 8774923 ST5 E A/G 0.21 −0.21 0.04 3.6 × 10‒8 0.33 0.96 0.61 1.2 × 10‒1
12 rs11067763 116198341 MED13L AS A/G 0.62 0.81 0.10 5.7 × 10‒16 0.78 0.42 0.68 5.4 × 10‒1
12 rs10858966 90567026 ATP2B1 E C/G 0.29 0.26 0.03 9.2 × 10‒15 0.02 0.86 2.17 6.9 × 10‒1
12 rs2024385 12888438 APOLD1 E A/T 0.42 −0.26 0.03 5.9 × 10‒18 0.46 −0.57 0.59 3.4 × 10‒1
12 rs11571376 1059556 RAD52 E C/G 0.70 −0.18 0.03 5.7 × 10‒8 0.73 −0.49 0.71 4.9 × 10‒1
12 rs6487543 26438189 SSPN E A/G 0.77 0.30 0.05 6.3 × 10‒10 0.08 −0.41 1.05 7.0 × 10‒1
12 rs2681492 90013089 ATP2B1 E/AS/AA G/A 0.17 −0.97 0.16 5.8 × 10‒8 0.15 1.84 0.79 2.1 × 10‒2
12 rs10850411 115387796 TBX5‐TBX3 E T/C 0.70 0.35 — 5.4 × 10‒8 0.61 −0.45 0.60 4.5 × 10‒1
12 rs17249754 90060586 ATP2B1 E G/A 0.84 0.93 — 1.8 × 10‒18 0.85 −1.58 0.80 4.8 × 10‒2
12 rs10437954 58003922 ARHGEF25 E A/G 0.90 −0.41 0.05 1.6 × 10‒14 0.67 0.61 0.66 3.5 × 10‒1
12 rs5742643 102837863 IGF1 E A/G 0.25 −0.22 0.03 2.0 × 10‒10 0.26 −0.67 0.69 3.3 × 10‒1
12 rs7963801 79685226 SYT1 E T/C 0.41 −0.24 0.03 2.8 × 10‒14 0.01 3.33 2.54 1.9 × 10‒1
12 rs7976167 24210599 SOX5 E T/C 0.69 0.18 0.03 3.8 × 10‒8 0.84 1.61 0.82 5.1 × 10‒2
13 rs9532243 32191408 RXFP2 E A/C 0.48 0.22 0.03 8.2 × 10‒14 0.55 −0.33 0.59 5.8 × 10‒1
13 rs606950 22298923 FGF9 E A/G 0.62 0.27 0.03 3.2 × 10‒18 0.47 0.88 0.60 1.4 × 10‒1
13 rs78474310 73826901 KLF5 E A/G 0.96 −0.47 0.07 1.5 × 10‒10 0.99 −0.72 3.38 8.3 × 10‒1
13 rs9526707 51489186 RNASEH2B E A/G 0.32 −0.20 0.03 2.7 × 10‒10 0.12 −1.59 0.91 8.0 × 10‒2
13 rs9549328 113636156 MCF2L E T/C 0.23 0.32 0.06 1.5 × 10‒8 0.15 0.59 0.89 5.1 × 10‒1
14 rs8014182 103859962 MARK3 E T/C 0.14 −0.33 0.04 5.2 × 10‒14 0.02 0.19 1.93 9.2 × 10‒1
14 rs11159091 75074316 LTBP2 E A/G 0.46 0.20 0.03 6.7 × 10‒11 0.01 2.00 2.77 4.7 × 10‒1
14 rs11623535 72462381 RGS6 E A/G 0.74 0.21 0.03 1.0 × 10‒9 0.57 0.71 0.60 2.4 × 10‒1
14 rs17115145 30122409 PRKD1 E T/C 0.40 0.18 0.03 7.4 × 10‒9 0.57 −0.33 0.58 5.7 × 10‒1
14 rs9888615 53377540 FERMT2 E T/C 0.29 −0.32 0.05 3.5 × 10‒10 0.62 0.38 0.63 5.4 × 10‒1
14 rs8016306 63928546 PPP2R5E E A/G 0.80 0.34 0.06 3.7 × 10‒9 0.15 −0.10 0.84 9.1 × 10‒1
15 rs1563894 68635775 TGA11 E A/G 0.19 −0.09 — 2.9 × 10‒8 0.69 0.17 0.63 7.8 × 10‒1
15 rs2521501 91437388 FURIN‐FES E T/A 0.31 0.65 — 5.2 × 10‒9 0.21 −0.39 0.76 6.1 × 10‒1
15 rs1378942 75077367 CYP1A1‐ULK3 E C/A 0.35 0.61 — 5.7 × 10‒23 0.97 −0.03 1.70 9.9 × 10‒1
15 rs35199222 81013037 ABHD17C E A/G 0.45 0.32 0.05 5.2 × 10‒12 0.07 0.39 1.18 7.5 × 10‒1
15 rs11632436 86295286 RP11−158M2.4 E C/G 0.50 0.22 0.03 2.0 × 10‒13 0.21 −0.31 0.73 6.7 × 10‒1
15 rs3743157 85680532 PDE8A E A/C 0.17 0.29 0.04 4.2 × 10‒13 0.71 0.10 0.66 8.8 × 10‒1
15 rs4965529 100145224 MEF2A E T/G 0.17 −0.26 0.04 5.4 × 10‒11 0.31 −0.16 0.64 8.0 × 10‒1
16 rs11639856 24788645 TNRC6A E/AA A/T 0.19 −0.34 0.06 1.3 × 10‒8 0.19 0.90 0.78 2.5 × 10‒1
16 rs11643209 75331044 CFDP1 E T/G 0.42 −0.34 0.05 1.8 × 10‒12 0.74 0.08 0.70 9.1 × 10‒1
16 rs7187540 85318302 LINC00311 E A/C 0.34 −0.20 0.03 1.0 × 10‒8 0.15 0.01 0.89 9.9 × 10‒1
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with BP at p < .05 by chance alone. None of the replicated 
SNPs met a Bonferroni corrected significance threshold 
(0.05/370 = 1.35 × 10−4), although one (rs6712094 intergenic 
between FIGN and GRB14) was very close (p = 2.6 × 10−4) 
for association with systolic BP. The most strongly associ-
ated SNPs for association with diastolic BP were rs805303 
between BAT2 and BAT5 (p  =  1.0  ×  10−3) and PDLIM5 
rs7694000 (p = 1.3 × 10−3).
4 |  DISCUSSION
To our knowledge, this is the first genetic analysis examining 
variants associated with BP among African adolescents. We hy-
pothesized that common genetic variants (unique or not unique 
to populations in Africa) were associated with systolic and, or 
diastolic BP in Ugandan adolescents and that these associations 
may overlap with associated variants identified in previous 
studies of Africans. The GWAS revealed no novel or previously 
identified variant associated with systolic or diastolic BP in our 
study population. Thirty‐three SNPs were associated with BP 
in the replication analysis, with the direction of effect consist-
ent with the discovery population for 14 SNPs. There were no 
SNPs reaching a Bonferroni‐adjusted significance level. None 
of the replicated SNPs were located in genes with monogenic 
effect on hypertension (Ehret & Caulfield, 2013).
The SNPs most strongly associated with either systolic or 
diastolic BP were of borderline significance and none have 
been reported as associated with BP in previous BP GWASs. 
The most strongly associated SNPs were mostly common 
variants with modest effect sizes and might uniquely in-
fluence BP in African population. It is important for larger 
genetic studies of African population to investigate the role 
of these SNPs in BP regulation among Africans. These top 
SNPs are potential candidates for replication analysis in 
African populations.
The failure to identify variants strongly associated with 
BP presumably occurred because the study was underpow-
ered to detect effects of rare variants or small effects of 
common variants. Blood pressure is most likely a polygenic 
Chr SNP Positiona Nearest gene Population
EA/
RA
Discovery sample EMaBS sample
EAF β SE p‐value EAF βb SE p‐value
17 rs4925159 18185510 TOP3A E A/G 0.43 0.22 0.03 9.7 × 10‒13 0.73 0.29 0.63 6.5 × 10‒1
17 rs34430710 56876627 PPM1E E A/T 0.68 −0.21 0.03 5.0 × 10‒11 0.89 0.95 0.89 2.9 × 10‒1
17 rs1036902 58950791 BCAS3 E T/C 0.84 −0.25 0.04 1.7 × 10‒9 0.19 −0.14 0.73 8.5 × 10‒1
17 rs1551355 30032420 RP11−805L22.1 E T/C 0.23 0.21 0.04 3.9 × 10‒9 0.03 −0.05 1.94 9.8 × 10‒1
17 rs12940887 47402807 ZNF652 E T/C 0.38 0.36 — 1.8 × 10‒10 0.07 −0.48 1.43 7.4 × 10‒1
17 rs57927100 75317300 SEPT9 E C/G 0.26 −0.31 0.05 4.0 × 10‒14 0.78 −0.60 0.70 3.9 × 10‒1
17 rs2467099 73949045 ACOX1 E T/C 0.22 −0.30 0.06 3.3 × 10‒8 0.12 −0.82 0.95 3.9 × 10‒1
17 rs12941318 1333598 CRK E T/C 0.49 −0.27 0.05 2.5 × 10‒8 0.75 0.67 0.66 3.1 × 10‒1
17 rs12946454 43208121 PLCD3 E T/A 0.28 0.50 0.17 1.0 × 10‒8 0.06 −0.06 1.20 9.6 × 10‒1
17 rs7406910 46688256 HOXB7 E/AS T/C 0.12 −0.46 — 3.8 × 10‒8 0.26 0.38 0.65 5.6 × 10‒1
17 rs112280096 79367409 RP11−1055B8.6 E A/C 0.36 −0.20 0.04 1.3 × 10‒9 0.06 0.68 1.45 6.4 × 10‒1
18 rs12958173 42141977 SETBP1 E A/C 0.31 0.36 0.05 1.4 × 10‒13 0.32 0.72 0.63 2.6 × 10‒1
18 rs12454712 60845884 BCL2 E T/C 0.62 0.19 0.03 5.8 × 10‒9 0.76 0.86 0.70 2.2 × 10‒1
18 rs10048404 54578482 WDR7 E T/C 0.37 −0.26 0.03 1.9 × 10‒16 0.05 −1.12 1.33 4.9 × 10‒1
18 rs11876341 48799991 MEX3C E A/G 0.69 −0.21 0.03 1.8 × 10‒10 0.94 2.01 1.48 1.8 × 10‒1
19 rs4247374 7252756 INSR E T/C 0.14 −0.59 0.08 1.2 × 10‒18 0.02 −0.93 2.23 6.7 × 10‒1
20 rs1327235 10969030 JAG1 E G/A 0.46 0.34 — 1.9 × 10‒8 0.59 −0.03 0.59 9.6 × 10‒1
20 rs6015450 57751117 GNAS‐EDN3 E G/A 0.12 0.90 — 3.9 × 10‒23 0.18 0.51 0.74 5.0 × 10‒1
21 rs12627651 44760603 CRYAA‐SIK1 E A/G 0.29 0.39 0.05 2.6 × 10‒14 0.07 1.70 1.28 5.9 × 10‒1
22 rs4823006 29451671 ZNRF3 E/AA G/A 0.42 −0.26 0.05 7.9 × 10‒9 0.40 0.86 0.58 1.4 × 10‒1
22 rs28578714 50727921 PLXNB2 E T/C 0.61 0.21 0.03 2.5 × 10‒10 0.53 −0.59 0.58 3.1 × 10‒1
Note: Bold indicate p < 5.0 × 10−2 for replication analysis.
Abbreviations: AA, African ancestry; AS, Asian ancestry; Chr, chromosomes; E, European ancestry; EA, effect allele; EAF, effect allele frequency; RA, reference al-
lele; SE, standard error; SNP, single nucleotide polymorphism; β, Effect size estimates correspond to mean difference in mmHg per effect allele for systolic or diastolic 
blood pressure, adjusted for age and body mass index.
aGiven with respect to Build 37 (GRCh37/hg19). 
bAdjusted for age and body mass index. 
cIndicate same β direction in both the discovery and EMaBS populations. 
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T A B L E  3  Loci associated with diastolic blood pressure identified from previous GWAS and results of replication in Entebbe Mother and 
Baby Study (EMaBS) sample
Chr SNP Positiona Nearest gene Population
EA/
RA
Discovery sample EMaBS sample
EAF β SE p‐value EAF βb SE p‐value
1 rs17367504 11862778 MTHFR/NPPB E G/A 0.15 −0.55 — 3.5 × 10‒19 0.09 −0.53 0.97 5.8 × 10‒1
1 rs2169137 204497913 MDM4 E/AS/AA G/C 0.27 −0.36 0.07 5.9 × 10‒8 0.23 1.32 0.61 3.1 × 10‒2
1 rs13306561 11865804 MTHFR E/AS/AA G/A 0.15 −0.52 0.09 3.0 × 10‒19 0.27 0.04 0.58 9.4 × 10‒1
1 rs2932538 113216543 MOV10 E G/A 0.75 0.24 — 9.9 × 10‒10 0.85 −0.25 0.70 3.6 × 10‒1
1 rs4846049 11850365 MTHFR‐NPPB E T/G 0.33 −0.55 0.10 6.7 × 10‒8 0.51 0.72 0.50 1.6 × 10‒1
1 rs6686889 25030470 chr1mb25 E T/C 0.25 0.19 0.03 3.6 × 10‒9 0.36 −0.28 0.53 5.9 × 10‒1
1 s12405515 172357441 DNM3 E T/G 0.56 −0.17 0.03 1.4 × 10‒9 0.20 0.68 0.66 3.0 × 10‒1
1 s12408022 217718789 GPATCH2 E T/C 0.26 0.20 0.03 2.4 × 10‒10 0.06 −0.43 1.14 7.1 × 10‒1
1 rs10916082 227252626 CDC42BPA E A/G 0.73 −0.18 0.03 8.4 × 10‒9 0.52 −0.06 0.52 9.1 × 10‒1
1 rs2760061 228191075 WNT3A E A/T 0.47 0.23 0.03 2.1 × 10‒16 0.62 −0.02 0.56 9.7 × 10‒1
1 rs953492 243471192 SDCCAG8 E A/G 0.46 0.22 0.03 7.4 × 10‒16 0.68 −0.18 0.56 7.5 × 10‒1
1 rs2004776 230848702 AGT E T/C 0.23 0.32 0.06 5.0 × 10‒8 0.52 −0.45 0.52 3.9 × 10‒1
1 rs1565716 29549216 MECR E A/G 0.07 0.21 0.03 3.5 × 10‒10 0.09 0.66 1.02 5.2 × 10‒1
1 rs35981664 218549354 TGFB2 E A/T 0.69 −0.16 0.02 2.0 × 10‒17 0.99 −0.58 3.69 8.8 × 10‒1
1 rs12142296 46541679 PIK3R3 E T/G 0.86 −0.16 0.03 8.9 × 10‒11 0.98 1.09 1.66 5.1 × 10‒1
1 rs72704264 145713305 CD160 E C/G 0.21 0.12 0.02 3.6 × 10‒8 0.03 0.58 1.44 6.9 × 10‒1
2 rs1446468 164963486 FIGN‐GRB14 E T/C 0.53 −0.50 0.07 6.9 × 10‒9 0.95 −0.61 1.17 6.1 × 10‒1
2 rs16823124 183224127 PDE1A E A/G 0.42 0.26 0.04 2.0 × 10‒10 0.11 −0.06 0.80 9.4 × 10‒1
2 rs55701159 25139596 ADCY3 E T/G 0.89 0.29 0.04 7.2 × 10‒11 0.89 −1.98 0.79 1.3 × 10‒2
2 rs4952611 40567743 SLC8A1 E T/C 0.58 −0.16 0.03 4.0 × 10‒8 0.72 −0.08 0.59 9.0 × 10‒1
2 rs2579519 96675166 GPAT2‐FAHD2CP E T/C 0.63 −0.20 0.03 4.8 × 10‒12 0.72 0.01 0.61 9.9 × 10‒1
2 rs7592578 191439591 TMEM194B E T/G 0.19 −0.24 0.04 9.5 × 10‒12 0.27 −0.81 0.61 1.8 × 10‒1
2 rs1063281 218668732 TNS1 E T/C 0.60 −0.20 0.03 1.3 × 10‒12 0.59 0.28 0.55 6.1 × 10‒1
2 rs1975487 55809054 PNPT1 E A/G 0.46 −0.16 0.03 1.8 × 10‒9 0.68 0.02 0.55 9.7 × 10‒1
2 rs1220128 158499902 ACVR1C E C/G 0.85 0.19 0.02 6.2 × 10‒15 0.40 0.20 0.53 7.1 × 10‒1
2 rs1996992 219651349 CYP27A1 E T/G 0.05 −0.30 004 4.7 × 10‒14 0.09 −1.00 0.93 2.8 × 10‒1
2 rs13001283 127183454 GYPC E A/G 0.16 0.15 0.02 1.9 × 10‒10 0.11 0.81 0.79 3.1 × 10‒1
2 rs7606205 144146311 ARHGAP15 E A/C 0.70 −0.13 0.02 2.4 × 10‒11 0.49 −0.40 0.53 4.5 × 10‒1
2 rs34570306 146272860 ZEB2 E T/C 0.53 −0.12 0.02 1.2 × 10‒11 0.07 −0.00 1.04 1.0 × 10‒1
2 rs4851462 98357163 ZAP70 E T/C 0.63 −0.12 0.02 4.0 × 10‒11 0.90 −0.46 0.91 6.2 × 10‒1
2 rs2707238 38094149 LINC00211 E C/G 0.28 0.10 0.02 6.8 × 10‒8 0.28 −0.42 0.60 4.8 × 10‒1
3 rs11128722 14958126 FGD5 E A/G 0.56 −0.17 0.03 5.1 × 10‒10 0.32 0.55 0.53 3.0 × 10‒1
3 rs918466 64710253 ADAMTS9 E A/G 0.41 −0.18 0.03 1.7 × 10‒11 0.90 0.57 0.86 5.1 × 10‒1
3 rs36022378 49913705 CAMKV‐
ACTBP13
E T/C 0.80 −0.20 0.03 4.7 × 10‒9 0.98 −0.37 2.44 8.8 × 10‒1
3 rs743757 50476378 CACNA2D2 E C/G 0.14 0.25 0.04 2.4 × 10‒10 0.55 −0.60 0.54 2.7 × 10‒1
3 s9827472 56726646 FAM208A E T/C 0.37 −0.18 0.03 4.3 × 10‒10 0.48 0.19 0.52 7.0 × 10‒1
3 rs2306374 138119952 MRAS E T/C 0.84 −0.18 0.03 7.4 × 10‒9 0.96 2.03 1.37 1.4 × 10‒1
3 rs12374077 185317674 SENP2 E C/G 0.35 0.16 0.03 9.2 × 10‒9 0.47 0.52 0.52 3.2 × 10‒1
3 rs143112823 154707967 RP11−439C8.2 E A/G 0.09 −0.40 0.05 1.4 × 10‒14 0.09 −0.41 0.99 6.8 × 10‒1
3 rs419076 169100886 MECOM E T/C 0.47 0.24 — 2.1 × 10‒12 0.57 −0.29 0.54 5.8 × 10‒1
3 rs319690 47927484 MAP4 E T/C 0.50 0.28 0.05 1.8 × 10‒8 0.44 0.26 0.55 6.3 × 10‒1
3 rs1706003 194299967 TMEM44 E T/G 0.47 0.12 0.02 5.8 × 10‒12 0.01 −3.51 2.17 1.1 × 10‒1
3 rs11923667 101268080 TRMT10C E A/T 0.41 0.12 0.02 3.1 × 10‒11 0.27 −1.06 0.57 6.5 × 10‒2
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Chr SNP Positiona Nearest gene Population
EA/
RA
Discovery sample EMaBS sample
EAF β SE p‐value EAF βb SE p‐value
3 rs6777317 197070959 DLG1 E A/G 0.92 0.12 0.02 1.5 × 10‒10 0.90 0.76 0.92 4.1 × 10‒1
3 rs4634143 23163749 UBE2E2 E T/C 0.30 0.12 0.02 7.9 × 10‒10 0.07 0.10 1.06 9.3 × 10‒1
3 rs3774372 41877414 ULK4 E T/C 0.83 −0.37 — 9.0 × 10‒14 0.77 −0.72 0.59 2.2 × 10‒1
4 rs13139571 156645513 GUCY1A3‐
GUCY1B3
E C/A 0.76 0.26 — 2.2 × 10‒10 0.86 0.89 0.75 2.4 × 10‒1
4 rs6825911 111381638 ENPEP AS C/T 0.51 0.39 0.07 9.0 × 10‒9 0.61 0.46 0.55 4.0 × 10‒1
4 rs2291435 38387395 TBC1D1‐FLJ13197 E/AA T/C 0.52 −0.16 0.03 4.3 × 10‒9 0.30 0.07 5.58 9.0 × 10‒1
4 rs66887589 120509279 PDE5A E T/C 0.52 −0.22 0.03 3.4 × 10‒15 0.62 −0.46 0.55 4.0 × 10‒1
4 rs1458038 81164723 FGF5 E T/C 0.29 0.46 — 8.5 × 10‒25 0.04 0.98 1.35 4.7 × 10‒1
4 rs223361 103769304 UBE2D3 E T/C 0.66 0.17 0.02 2.7 × 10‒20 0.48 −0.10 0.54 8.5 × 10‒1
4 rs28667801 26785356 STIM2 E A/T 0.59 −0.16 0.02 1.9 × 10‒19 0.87 −0.01 0.78 9.9 × 10‒1
4 rs55829085 2165493 POLN E A/C 0.95 −0.28 0.04 3.0 × 10‒11 0.99 2.13 2.50 4.0 × 10‒1
4 rs7694000 95324968 PDLIM5 E A/T 0.54 −0.10 0.02 3.5 × 10‒8 0.21 2.03 0.63 1.3 × 10‒3
4 rs62312401 116987529 NDST4‐TRAM1L1 AA C/G 0.94 1.13 0.24 3.5 × 10‒9 0.04 −2.14 1.39 1.3 × 10‒1
5 rs12521868 131784393 C5orf56 E T/G 0.37 −0.19 — 6.1 × 10‒11 0.04 −0.06 1.44 9.6 × 10‒1
5 rs1173771 32815028 NPR3‐C5orf23 E G/A 0.60 0.26 — 9.1 × 10‒12 0.82 1.04 0.72 1.5 × 10‒1
5 rs11953630 157845402 EBF1 E T/C 0.37 −0.28 — 3.8 × 10‒13 0.13 1.27 0.77 9.9 × 10‒2
5 rs10077885 114390121 TRIM36 E A/C 0.50 −0.17 0.03 4.0 × 10‒11 0.65 −0.40 0.55 4.7 × 10‒1
5 rs6891344 123136656 CSNK1G3 E A/G 0.82 0.23 0.03 1.6 × 10‒11 0.72 0.45 0.56 4.1 × 10‒1
5 rs10078021 75038431 POC5 E T/G 0.63 −0.16 0.03 1.3 × 10‒8 0.15 −0.41 0.69 5.5 × 10‒1
5 rs72812846 173377636 CPEB4 E A/T 0.28 −0.21 0.03 2.2 × 10‒11 0.04 −0.18 1.43 9.0 × 10‒1
5 rs10062049 61553881 KIF2A E T/C 0.14 0.22 0.02 4.5 × 10‒18 0.32 0.62 0.63 3.2 × 10‒1
5 rs954767 3706050 IRX1 E A/C 0.74 −0.15 0.02 4.2 × 10‒14 0.68 1.14 0.54 3.6 × 10‒2
5 rs55747751 132397351 HSPA4 E A/G 0.08 −0.22 0.03 1.4 × 10‒11 0.01 −0.17 2.43 9.4 × 10‒1
5 rs4286632 66291370 MAST4 E A/G 0.73 0.12 0.02 1.9 × 10‒9 0.84 1.50c 0.74 4.3 × 10‒2
5 rs2188962 131770805 C5orf56 E/AA T/C 0.37 −0.20 0.03 3.0 × 10‒11 0.03 1.25 1.70 4.6 × 10‒1
5 rs12515541 57095011 ACTBL2 E T/G 0.61 0.12 0.02 6.2 × 10‒11 0.49 0.08 0.54 8.9 × 10‒1
6 rs926552 29548089 SNORD32B E/AA T/C 0.11 −0.26 0.05 7.2 × 10‒8 0.21 −0.25 0.63 7.0 × 10‒1
6 rs10943605 79655477 PHIP E/AA A/G 0.46 0.16 0.03 3.3 × 10‒9 0.28 0.10 0.57 8.6 × 10‒1
6 rs13205180 51832494 PKHD1 E T/C 0.49 0.17 0.03 7.0 × 10‒10 0.12 0.43 0.81 6.0 × 10‒1
6 rs9372498 118572486 SLC35F1 E A/T 0.08 0.33 0.05 1.8 × 10‒11 0.10 0.11 0.87 9.0 × 10‒1
6 rs147212971 166178451 PDE10A E T/C 0.06 −0.36 0.06 1.6 × 10‒9 0.17 0.34 0.74 6.5 × 10‒1
6 rs1799945 26091179 HFE E G/C 0.14 0.46 — 1.5 × 10‒15 0.02 −0.43 1.90 8.2 × 10‒1
6 rs805303 31616366 BAT2‐BAT5 E G/A 0.61 0.23 — 3.0 × 10‒11 0.40 1.75c 0.54 1.0 × 10‒3
6 rs13209747 127115454 RSPO3 E/AA/AS T/C 0.19 0.56 0.12 2.4 × 10‒11 0.07 −0.50 0.96 6.0 × 10‒1
6 rs17080102 151004770 PLEKHG1 E/AA/AS C/G 0.10 −0.74 0.15 1.9 × 10‒11 0.15 −1.21 0.70 8.8 × 10‒2
6 rs9472135 43809802 VEGFA E T/C 0.70 0.15 0.02 4.3 × 10‒16 0.77 0.58 0.62 3.5 × 10‒1
6 rs668459 139835689 CITED2 E T/C 0.59 −0.11 0.02 1.0 × 10‒10 0.28 0.02 0.57 9.7 × 10‒1
6 rs598682 154418759 OPRM1 E A/G 0.25 −0.11 0.02 7.2 × 10‒8 0.03 0.23 1.31 8.6 × 10‒1
7 rs17428471 27337867 EVX1‐HOXA E/AA/AS T/G 0.14 0.61 0.14 1.6 × 10‒9 0.13 2.01c 0.79 1.1 × 10‒2
7 rs2969070 2512545 CHST12‐LFNG E A/G 0.63 −0.18 0.03 2.9 × 10‒11 0.97 −0.24 1.58 8.8 × 10‒1
7 rs11556924 129663496 ZC3HC1 E T/C 0.38 −0.21 0.03 8.2 × 10‒15 0.01 6.90 2.72 1.2 × 10‒2
7 rs6969780 27159136 HOXA3 E/AA C/G 0.13 0.26 0.05 1.1 × 10‒8 0.39 0.68 0.54 2.1 × 10‒1
7 rs891511 150704843 NOS3 E/AA A/G 0.37 −0.26 0.03 2.0 × 10‒16 0.59 −0.55 0.52 3.0 × 10‒1
7 rs1947228 96461649 SHFM1 E T/C 0.42 −0.14 0.02 2.6 × 10‒16 0.96 1.01 1.29 4.4 × 10‒1
7 rs1722886 134215259 AKR1B10 E A/T 0.57 0.12 0.02 3.8 × 10‒12 0.29 −0.05 0.57 9.3 × 10‒1
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Chr SNP Positiona Nearest gene Population
EA/
RA
Discovery sample EMaBS sample
EAF β SE p‐value EAF βb SE p‐value
7 rs9638084 156311745 LINC01006 E A/G 0.40 0.12 0.02 8.5 × 10‒11 0.55 −0.40 0.51 4.3 × 10‒1
7 rs11563582 27351650 EVX1‐HOXA AA A/G 0.13 1.02 0.17 8.4 × 10‒10 0.17 0.80 0.71 2.6 × 10‒1
8 rs78192203 142375073 GPR20 AA T/A 0.80 0.77 0.14 1.3 × 10‒8 0.79 −0.29 0.65 6.5 × 10‒1
8 rs2978098 101676675 SNX31 E A/C 0.54 0.17 0.03 1.5 × 10‒9 0.03 −0.02 1.70 9.9 × 10‒1
8 rs62524579 144060955 P11‒273G15.2 E A/G 0.53 −0.18 0.03 3.8 × 10‒9 0.37 0.28 0.55 6.2 × 10‒1
8 rs10087782 141858620 PTK2 E T/C 0.45 0.13 0.02 3.0 × 10‒14 0.82 0.32 0.67 6.3 × 10‒1
8 rs1047030 22428708 SORBS3 E A/G 0.81 0.13 0.02 5.7 × 10‒8 0.96 −0.80 1.23 5.2 × 10‒1
9 rs4364717 21801530 MTAP E A/G 0.55 −0.18 0.03 1.3 × 10‒10 0.24 0.33 0.61 5.8 × 10‒1
9 rs76452347 35906471 HRCT1 E/AA T/C 0.19 −0.23 0.04 6.8 × 10‒10 0.09 −0.16 0.92 8.6 × 10‒1
9 rs7020564 109670016 ZNF462 E A/C 0.70 −0.11 0.02 6.7 × 10‒9 0.12 −0.54 0.82 5.1 × 10‒1
10 rs4746172 75855842 VCL E C/T — 0.23 0.04 9.1 × 10‒8 0.23 −0.49 0.66 4.6 × 10‒1
10 rs1801253 115805056 ADRB1 E G/C 0.27 −0.36 0.06 9.5 × 10‒10 0.34 −0.45 0.56 4.2 × 10‒1
10 rs10995311 64564934 ADO E/AA G/C 0.38 −0.20 0.03 2.1 × 10‒11 0.03 1.36 1.47 3.6 × 10‒1
10 rs1530440 63524591 C10orf107 E T/C 0.19 −0.39 0.06 1.0 × 10‒9 0.03 −0.87 1.58 5.8 × 10‒1
10 rs4590817 63467553 C10orf107 E G/C 0.84 0.42 — 1.3 × 10‒12 0.84 −0.81 0.68 2.4 × 10‒1
10 rs2782980 115781527 ADRB1 E T/C 0.20 −0.28 0.05 9.6 × 10‒8 0.47 −0.76 0.53 1.5 × 10‒1
10 rs1813353 18707448 CACNB2 E T/C 0.68 0.42 — 2.3 × 10‒15 0.84 0.16 0.73 8.3 × 10‒1
10 rs603424 102075479 PKD2L1 E A/G 0.18 0.18 0.02 1.2 × 10‒14 0.75 0.36 0.63 5.7 × 10‒1
10 rs10906391 13523937 BEND7 E T/C 0.32 0.13 0.02 7.6 × 10‒12 0.03 −0.27 1.65 8.6 × 10‒1
10 rs4373814 18419972 CACNB2(5′) E G/C 0.55 −0.22 — 4.4 × 10‒10 0.39 −0.35 0.53 5.1 × 10‒1
10 rs11191548 104846178 CYP17A1/NT5C2 E T/C 0.91 0.46 — 9.4 × 10‒13 0.98 1.23 1.42 3.9 × 10‒1
11 rs4601790 65353906 EHBP1L1 E/AS G/A 0.27 −0.02 0.04 9.9 × 10‒9 0.06 −0.32 1.05 7.6 × 10‒1
11 rs7103648 47461783 RAPSN‐PSMC3‐
SLC39A13
E A/G 0.61 −0.24 0.03 9.0 × 10‒19 0.85 0.78 0.74 3.0 × 10‒1
11 rs751984 61278246 LRRC10B E T/C 0.88 0.38 0.04 4.2 × 10‒20 0.79 1.56c 0.63 1.4 × 10‒2
11 rs900145 13293905 ARNTL E/AA G/A 0.34 −0.20 0.03 1.8 × 10‒8 0.52 0.97 0.54 7.0 × 10‒2
11 rs11030119 27728102 BDNF E A/G 0.31 −0.16 0.03 2.9 × 10‒8 0.35 −0.36 0.54 5.1 × 10‒1
11 rs67330701 69079707 MYEOV E T/C 0.09 −0.37 0.05 2.1 × 10‒12 0.01 0.92 2.27 6.9 × 10‒1
11 rs633185 100593538 FLJ32810‐
TMEM133
E G/C 0.28 −0.33 — 2.0 × 10‒15 0.23 −1.49c 6.23 1.7 × 10‒2
11 rs381815 16902268 PLEKHA7 E T/C 0.26 0.35 — 5.3 × 10‒14 0.26 0.58 0.62 3.4 × 10‒1
11 rs1401454 16250183 SOX6 E/AA/AS T/C 0.46 0.45 0.10 5.1 × 10‒10 0.46 −0.27 0.52 6.1 × 10‒1
11 rs360153 9762274 SWAP70 E T/C 0.42 −0.22 0.02 4.4 × 10‒36 0.52 −0.30 0.52 5.7 × 10‒1
11 rs11026586 22515533 RP11−34N19.1 E A/G 0.07 0.29 0.03 2.7 × 10‒17 0.06 0.43 1.21 7.3 × 10‒1
11 rs875106 70005641 ANO1 E A/G 0.52 −0.13 0.02 1.7 × 10‒14 0.71 1.02 5.8 7.7 × 10‒2
11 rs4420291 74374950 POLD3 E A/G 0.51 0.10 0.02 2.2 × 10‒8 0.33 0.08 0.58 8.9 × 10‒1
11 rs7129220 10350538 ADM E G/A 0.89 −0.30 — 6.4 × 10‒8 0.92 −0.79c 1.01 4.4 × 10‒3
12 rs17249754 90060586 ATP2B1 E G/A 0.84 0.52 — 1.2 × 10‒18 0.85 −1.89 0.69 7.0 × 10‒1
12 rs10850411 115387796 TBX5/TBX3 E T/C 0.70 0.25 — 5.4 × 10‒10 0.61 0.32 0.53 5.5 × 10‒1
12 rs1060105 123806219 SBNO1 E/AS T/C 0.21 −0.18 — 3.1 × 10‒8 0.05 −1.08 1.22 3.8 × 10‒1
12 rs2384550 115352731 TBX5‐TBX3 E A/G 0.35 −0.35 0.06 3.7 × 10‒8 0.35 −0.93 0.53 7.9 × 10‒2
12 rs35444 115552437 TBX3 AS A/G 0.75 0.50 0.05 1.3 × 10‒10 0.56 −0.66 0.53 2.1 × 10‒1
12 rs7302981 50537815 CERS5 E/AA A/G 0.34 0.25 0.03 9.4 × 10‒19 0.10 0.90 0.84 2.8 × 10‒1
12 rs7132012 8832203 RP11−20D14.4 E A/G 0.68 0.15 0.02 3.2 × 10‒17 0.57 0.08 0.51 8.8 × 10‒1
12 rs1271309 124820705 NCOR2 E A/G 0.16 −0.20 0.02 1.5 × 10‒16 0.08 0.22 0.92 8.1 × 10‒1
12 rs7137749 57098040 NACA E T/C 0.37 0.14 0.02 7.2 × 10‒15 0.52 −0.44 0.52 4.1 × 10‒1
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Chr SNP Positiona Nearest gene Population
EA/
RA
Discovery sample EMaBS sample
EAF β SE p‐value EAF βb SE p‐value
12 rs7134060 96717095 CDK17 E A/G 0.45 −0.11 0.02 1.1 × 10‒9 0.26 −0.93 0.60 1.2 × 10‒1
12 rs75507123 5417856 RP11−1038A11.3 E T/G 0.13 −0.14 0.03 3.9 × 10‒8 0.02 −0.66 1.70 7.0 × 10‒1
12 rs1098708 27321112 STK38L E A/G 0.28 −0.10 0.02 4.6 × 10‒8 0.82 1.08 0.67 1.1 × 10‒1
13 rs55684003 97988689 MBNL2 E A/G 0.70 0.12 0.02 1.0 × 10‒10 0.95 −1.83 1.14 1.1 × 10‒1
13 rs9563529 58316637 PCDH17 E T/G 0.21 0.12 0.02 1.4 × 10‒8 0.26 0.56 0.59 3.4 × 10‒1
14 rs11628933 60700903 PPM1A E C/G 0.23 −0.12 0.02 3.1 × 10‒9 0.40 −0.41 0.54 4.5 × 10‒1
14 rs4424827 35110857 SNX6 E T/C 0.57 −0.10 0.02 2.1 × 10‒8 0.94 −0.38 7.20 9.6 × 10‒1
15 rs7178615 66869072 RP11‒321F6.1 E A/G 0.37 −0.18 0.03 2.6 × 10‒10 0.19 1.42 0.69 4.1 × 10‒2
15 rs62012628 79070000 ADAMTS7 E T/C 0.29 −0.24 0.03 5.1 × 10‒12 0.31 −0.03 0.58 9.6 × 10‒1
15 rs12906962 95312071 chr15mb95 E T/C 0.68 −0.22 0.03 5.6 × 10‒14 0.21 −0.73 0.64 2.5 × 10‒1
15 rs1378942 75077367 CYP1A1‐ULK3 E C/A 0.36 0.48 0.09 6.0 × 10‒8 0.97 2.99c 1.48 4.4 × 10‒2
15 rs2521501 91437388 FURIN‐FES E T/A 0.31 0.36 — 1.9 × 10‒15 0.21 −1.11 0.66 9.5 × 10‒2
15 rs873122 92702020 SLCO3A1 E C/G 0.72 0.12 0.02 6.5 × 10‒10 0.94 2.00 1.16 8.5 × 10‒2
15 rs7180952 85162551 ZSCAN2 E T/C 0.54 −0.10 0.02 9.8 × 10‒9 0.75 0.02 0.61 9.8 × 10‒1
15 rs62004794 68454523 PIAS1 E A/G 0.44 −0.10 0.02 3.4 × 10‒8 0.60 −1.16c 0.55 3.6 × 10‒2
16 rs12921187 4943019 PPL E T/G 0.43 −0.17 0.03 2.5 × 10‒10 0.96 −2.36 1.23 5.5 × 10‒2
16 rs72799341 30936743 FBXL19 E A/G 0.24 0.19 0.03 5.8 × 10‒9 0.09 0.03 0.90 9.8 × 10‒1
16 rs8059962 81574197 CMIP E T/C 0.42 −0.17 0.03 1.3 × 10‒9 0.61 0.37 0.52 4.8 × 10‒1
16 rs1126464 89704365 DPEPI E/AA C/G 0.22 0.24 0.03 2.4 × 10‒13 0.06 −0.90 1.10 4.2 × 10‒1
16 rs45474499 66914492 PDP2 E T/C 0.05 0.36 0.04 8.5 × 10‒18 0.07 0.85 1.09 4.3 × 10‒1
16 rs7185555 69131281 HAS3 E C/G 0.15 −0.15 0.02 2.3 × 10‒10 0.31 0.42 0.56 4.6 × 10‒1
16 rs9932866 706067 WDR90 E A/G 0.37 0.12 0.02 2.9 × 10‒10 0.90 −1.61 0.80 4.5 × 10‒2
17 rs4308 61559625 ACE E A/G 0.37 0.21 0.03 6.8 × 10‒14 0.03 −1.29 1.73 4.5 × 10‒1
17 rs12940887 47402807 ZNF652 E T/C 0.38 0.27 — 2.3 × 10‒14 0.07 0.41 1.25 7.4 × 10‒1
18 rs12958173 42141977 SETBP1 E A/C 0.31 0.18 0.03 5.8 × 10‒10 0.31 0.68 0.56 2.2 × 10‒1
18 rs745821 48142854 MAPK4 E T/G 0.76 0.19 0.03 1.4 × 10‒9 0.70 0.21 0.58 7.1 × 10‒1
18 rs34163044 51851616 STARD6 E A/C 0.42 0.15 0.02 9.6 × 10‒17 0.31 −0.13 0.59 8.3 × 10‒1
18 rs11665020 10879503 PIEZO2 E C/G 0.32 −0.14 0.02 2.8 × 10‒14 0.14 −0.18 0.72 8.1 × 10‒1
18 rs4800420 20158965 CTAGE1 E A/G 0.29 0.12 0.02 5.2 × 10‒10 0.17 −0.63 0.70 3.7 × 10‒1
19 rs167479 11526765 RGL3 E/AA T/G 0.45 −0.30 0.03 4.2 × 10‒28 0.17 −0.23 0.71 7.4 × 10‒1
19 rs62104477 30294991 CCNE1 E T/G 0.33 0.18 0.03 1.2 × 10‒9 0.25 0.47 0.61 4.4 × 10‒1
19 rs4247374 7252756 INSR E T/C 0.14 −0.39 0.03 2.1 × 10‒22 0.02 −1.85 1.96 3.5 × 10‒1
19 rs2304130 19789528 ZNF101 E/AS A/G 0.91 −0.29 — 2.0 × 10‒8 0.74 −0.63 0.59 2.9 × 10‒1
19 rs9710247 40760449 AKT2 E A/G 0.45 0.16 0.03 1.6 × 10‒9 0.90 −1.29 0.92 1.6 × 10‒1
19 rs1821295 32590773 AC011518.1 E T/C 0.70 −0.14 0.02 3.1 × 10‒13 0.92 −0.06 1.14 9.6 × 10−1
20 rs6095241 47308798 PREX1 E/AS A/G 0.45 −0.17 — 4.8 × 10−9 0.60 −0.42 0.53 4.4 × 10−1
20 rs6108168 8626271 PLCB1 E A/C 0.25 −0.21 0.03 1.1 × 10−11 0.62 −0.08 0.53 8.8 × 10−1
20 rs1327235 10969030 JAG1 E G/A 0.46 0.30 — 1.4 × 10−15 0.59 −0.09 0.52 8.6 × 10−1
20 rs6015450 57751117 GNAS‐EDN3 E G/A 0.12 0.56 — 5.6 × 10−23 0.18 0.74 0.65 2.6 × 10−1
20 rs1232482 11886643 BTBD3 E T/C 0.40 −0.12 0.02 6.1 × 10−12 0.18 −1.26 0.70 7.3 × 10−2
21 rs12627651 44760603 CRYAA‐SIK1 E A/G 0.29 0.20 0.03 1.4 × 10−11 0.07 2.55c 1.12 2.3 × 10−2
Note: Bold indicate p < 5.0 × 10−2 for replication analysis.
Abbreviations: AA, African ancestry; AS, Asian ancestry; Chr, chromosomes; E, European ancestry; EA, effect allele; EAF, effect allele frequency; RA, reference al-
lele; SE, standard error;SNP, single nucleotide polymorphism; β, Effect size estimates correspond to mean difference in mmHg per effect allele for systolic or diastolic 
blood pressure, adjusted for age and body mass index.
aGiven with respect to Build 37 (GRCh37/hg19). 
bAdjusted for age and body mass index. 
cIndicate same β direction in both the discovery and EMaBS populations. 
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trait influenced by the simultaneous presence of several 
gene variants each with a small effect size and contributing 
in an additive manner to BP expression. Thus, the large 
effect sizes that this study had good power to detect, may 
not be realistic. For example, the present study had 80% 
power to detect a 3.2 mmHg change in mean systolic BP 
for a minor allele frequency of 20% at genome‐wide signif-
icance level, p < 5 × 10−8. Many of the variants reliably as-
sociated with BP in adults have an effect size of 0.5 mmHg 
or less (Evangelou et al., 2018). In addition to the limita-
tion caused by the relatively small sample size, imputation 
did not allow inference for rare variants not included in the 
imputation SNP panel.
Few GWAS “top SNPs” from non‐African populations 
have been replicated in populations of African ancestry 
(Adeyemo et al., 2009; Franceschini et al., 2013; Kayima 
et al., 2017). Variants associated with BP in populations of 
African origin might be different from variants that influ-
ence BP in Caucasian populations or not in LD with the BP 
causing variants. Our replication study was limited to vari-
ants associated with BP from previous GWAS of BP in other 
populations. Thirty‐three SNPs identified from previous BP 
GWAS were replicated, most of these were previously iden-
tified in populations of non‐African origins. Of the identi-
fied loci, PAX2 is essential in the development of the renal 
epithelium (Dressler & Woolf, 1999) and plays a critical role 
in kidney development (Hou, Chen, & Wang, 2011). The 
kidneys are critical in BP regulation. Two of the replicated 
SNPs are located on ATP2B1. ATP2B1 is involved in cal-
cium homeostasis (Hirawa, Fujiwara, & Umemura, 2013). 
The ATP2B1 rs2681492, MDM4 rs2169137, EVX1/HOXA 
rs17428471 SNPs previously associated with BP in transeth-
nic populations (African, Caucasian and Asian) were asso-
ciated with adolescent BP in the present study. These genes 
most likely influence BP across different ethnic groups.
Replication studies in diverse populations have returned 
mixed results. This current study conducted 370 tests using 
330 SNPs, of which 33 SNPs (one SNP for both traits) were 
associated with BP. Failure to replicate most variants associ-
ated with BP in other populations could be due to differences 
in minor allele frequencies across populations or differences 
in LD patterns combined with a poor understanding of the 
causative variants or due to spurious initial findings. Blood 
pressure is likely to be influenced by the simultaneous pres-
ence of several genetic variants, each conferring a small 
change in BP.
Although none of the variants reached Bonferroni level 
of significance more associated variants were identified than 
expected under the null suggesting that some of these vari-
ants found to be associated could be worthy of further follow‐
up. Fourteen variants more than those expected by chance (19 
variants) under the null hypothesis were associated with BP 
in this study.
Of the 40 SNPs tested for association with both traits, 
only BAT2/BAT5 rs805303 was associated with both traits in 
the adolescents, suggesting that not many genetic loci have 
influence on both systolic and diastolic BP. Similar to an 
earlier replication study among adult Ugandans (Kayima et 
al., 2017), the ATP2B1 rs2681492 was associated with BP 
in these Ugandan adolescents, but with an opposite effect di-
rection to the discovery population (Hoffmann et al., 2017) 
and Ugandan adults (Kayima et al., 2017). The G allele of 
the ATP2B1 rs2681492 was associated with lower systolic 
BP in Ugandans adults (Kayima et al., 2017) but with higher 
systolic BP in the present study.
Some loci may have varying roles in BP regulation across 
different populations. A European study investigated SNPs 
associated with BP at different age epochs (using indepen-
dent samples for each age group): prepuberty (age 4–7 years), 
pubertal (8–12 years), and postpubertal (13–20 years). The A 
allele of TGA11 rs1563894 was associated with lower systolic 
BP in prepuberty while the T allele of SMARCA2/VLDLR 
rs872256 was associated with higher systolic BP during 
puberty (Parmar et al., 2016). No SNP was associated with 
BP in the postpubertal period, and no SNP was consistently 
associated with BP across all three age groups. The TGA11 
rs1563894 and SMARCA2/VLDLR rs872256 were not repli-
cated in this present study.
The present study has several strengths. This is the first BP 
GWAS of an African population and the first candidate gene 
analysis among adolescents residing in Africa. Participants 
in this study were similar to nonparticipants with respect to 
most baseline characterizes. Rigorous quality control pro-
cedures were used during the measurement of the various 
variables including BP and genotyping. Data from this study 
can contribute to future BP GWAS meta‐analyses. Key lim-
itations of this study were that it was underpowered to detect 
effects of rare variants and to enable testing for effect modifi-
cation by sex and other environmental variables, and the lack 
of a replication sample from a similar setting with which to 
confirm our GWAS findings.
Future work should take advantage of various African co-
horts to form consortia that can enable the conduct of GWAS 
meta‐analysis well powered to identify rare and low‐fre-
quency variants that may be associated with BP in African 
populations. Future candidate gene analysis using a sample 
from a different geographical region or ethnic background 
should investigate for interactions between variants, this 
might help our understanding of the etiology of BP. It is pos-
sible that multiple interacting variants (rare and common) are 
influencing BP levels in this population. Although we did not 
formally allow for multiple testing in the replication analysis, 
the current study had 33 associated SNPs 14 more than ex-
pected by chance. Polygenic scores analysis of variants asso-
ciated with BP among African populations may explain the 
missing BP heritability.
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In summary, we conducted the first genetic study of BP 
phenotypes among Ugandan adolescents. Although this study 
did not identify novel BP variants, replication of some previ-
ously identified variants suggests that some genetic variants 
may universally influence BP susceptibility. Large scale stud-
ies in African populations are required to identify novel and 
evaluate previously reported loci.
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